Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Chiral cyclohexane 1,3-diones as inhibitors of mutant SOD1-dependent protein aggregation for the treatment of ALS.

Zhang Y, Benmohamed R, Zhang W, Kim J, Edgerly CK, Zhu Y, Morimoto RI, Ferrante RJ, Kirsch DR, Silverman RB.

ACS Med Chem Lett. 2012 May 22;3(7):584-587. Erratum in: ACS Med Chem Lett. 2017 Feb 24;8(3):377.

2.

Cyclohexane 1,3-diones and their inhibition of mutant SOD1-dependent protein aggregation and toxicity in PC12 cells.

Zhang W, Benmohamed R, Arvanites AC, Morimoto RI, Ferrante RJ, Kirsch DR, Silverman RB.

Bioorg Med Chem. 2012 Jan 15;20(2):1029-45. doi: 10.1016/j.bmc.2011.11.039. Epub 2011 Nov 30.

3.

ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis.

Chen T, Benmohamed R, Kim J, Smith K, Amante D, Morimoto RI, Kirsch DR, Ferrante RJ, Silverman RB.

J Med Chem. 2012 Jan 12;55(1):515-27. doi: 10.1021/jm2014277. Epub 2011 Dec 22.

PMID:
22191331
4.

Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis.

Xia G, Benmohamed R, Kim J, Arvanites AC, Morimoto RI, Ferrante RJ, Kirsch DR, Silverman RB.

J Med Chem. 2011 Apr 14;54(7):2409-21. doi: 10.1021/jm101549k. Epub 2011 Mar 4.

5.

PACAP signaling exerts opposing effects on neuroprotection and neuroinflammation during disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.

Ringer C, Büning LS, Schäfer MK, Eiden LE, Weihe E, Schütz B.

Neurobiol Dis. 2013 Jun;54:32-42. doi: 10.1016/j.nbd.2013.02.010. Epub 2013 Mar 4.

6.

Rab1-dependent ER-Golgi transport dysfunction is a common pathogenic mechanism in SOD1, TDP-43 and FUS-associated ALS.

Soo KY, Halloran M, Sundaramoorthy V, Parakh S, Toth RP, Southam KA, McLean CA, Lock P, King A, Farg MA, Atkin JD.

Acta Neuropathol. 2015 Nov;130(5):679-97. doi: 10.1007/s00401-015-1468-2. Epub 2015 Aug 23.

PMID:
26298469
7.

Calcium dysregulation, mitochondrial pathology and protein aggregation in a culture model of amyotrophic lateral sclerosis: mechanistic relationship and differential sensitivity to intervention.

Tradewell ML, Cooper LA, Minotti S, Durham HD.

Neurobiol Dis. 2011 Jun;42(3):265-75. doi: 10.1016/j.nbd.2011.01.016. Epub 2011 Feb 3.

PMID:
21296666
8.

Strategies for stabilizing superoxide dismutase (SOD1), the protein destabilized in the most common form of familial amyotrophic lateral sclerosis.

Auclair JR, Boggio KJ, Petsko GA, Ringe D, Agar JN.

Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21394-9. doi: 10.1073/pnas.1015463107. Epub 2010 Nov 22.

9.

Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS.

Haenggeli C, Julien JP, Mosley RL, Perez N, Dhar A, Gendelman HE, Rothstein JD.

Neurobiol Dis. 2007 Apr;26(1):146-52. Epub 2006 Dec 30.

PMID:
17276077
10.

Knocking down metabotropic glutamate receptor 1 improves survival and disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.

Milanese M, Giribaldi F, Melone M, Bonifacino T, Musante I, Carminati E, Rossi PI, Vergani L, Voci A, Conti F, Puliti A, Bonanno G.

Neurobiol Dis. 2014 Apr;64:48-59. doi: 10.1016/j.nbd.2013.11.006. Epub 2013 Dec 19.

11.

Neuroprotective effect of activity-dependent neurotrophic factor against toxicity from familial amyotrophic lateral sclerosis-linked mutant SOD1 in vitro and in vivo.

Chiba T, Hashimoto Y, Tajima H, Yamada M, Kato R, Niikura T, Terashita K, Schulman H, Aiso S, Kita Y, Matsuoka M, Nishimoto I.

J Neurosci Res. 2004 Nov 15;78(4):542-52.

PMID:
15478191
12.

Correction to "Chiral Cyclohexane 1,3-Diones as Inhibitors of Mutant SOD1-Dependent Protein Aggregation for the Treatment of ALS".

Zhang Y, Benmohamed R, Zhang W, Kim J, Edgerly CK, Zhu Y, Morimoto RI, Ferrante RJ, Kirsch DR, Silverman RB.

ACS Med Chem Lett. 2017 Feb 24;8(3):377. doi: 10.1021/acsmedchemlett.7b00070. eCollection 2017 Mar 9.

13.

Heat shock factor 1 over-expression protects against exposure of hydrophobic residues on mutant SOD1 and early mortality in a mouse model of amyotrophic lateral sclerosis.

Lin PY, Simon SM, Koh WK, Folorunso O, Umbaugh CS, Pierce A.

Mol Neurodegener. 2013 Nov 21;8:43. doi: 10.1186/1750-1326-8-43.

14.

Over-expression of Hsp27 does not influence disease in the mutant SOD1(G93A) mouse model of amyotrophic lateral sclerosis.

Krishnan J, Vannuvel K, Andries M, Waelkens E, Robberecht W, Van Den Bosch L.

J Neurochem. 2008 Sep;106(5):2170-83. doi: 10.1111/j.1471-4159.2008.05545.x. Epub 2008 Jul 4.

15.

Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis.

Benmohamed R, Arvanites AC, Kim J, Ferrante RJ, Silverman RB, Morimoto RI, Kirsch DR.

Amyotroph Lateral Scler. 2011 Mar;12(2):87-96. doi: 10.3109/17482968.2010.522586. Epub 2010 Nov 12.

PMID:
21073276
16.

Diapocynin and apocynin administration fails to significantly extend survival in G93A SOD1 ALS mice.

Trumbull KA, McAllister D, Gandelman MM, Fung WY, Lew T, Brennan L, Lopez N, Morré J, Kalyanaraman B, Beckman JS.

Neurobiol Dis. 2012 Jan;45(1):137-44. doi: 10.1016/j.nbd.2011.07.015. Epub 2011 Jul 28.

17.

Zinc pre-treatment enhances NMDAR-mediated excitotoxicity in cultured cortical neurons from SOD1(G93A) mouse, a model of amyotrophic lateral sclerosis.

Nutini M, Frazzini V, Marini C, Spalloni A, Sensi SL, Longone P.

Neuropharmacology. 2011 Jun;60(7-8):1200-8. doi: 10.1016/j.neuropharm.2010.11.001. Epub 2010 Nov 5.

PMID:
21056589
18.

Impaired extracellular secretion of mutant superoxide dismutase 1 associates with neurotoxicity in familial amyotrophic lateral sclerosis.

Turner BJ, Atkin JD, Farg MA, Zang DW, Rembach A, Lopes EC, Patch JD, Hill AF, Cheema SS.

J Neurosci. 2005 Jan 5;25(1):108-17.

19.

Trehalose decreases mutant SOD1 expression and alleviates motor deficiency in early but not end-stage amyotrophic lateral sclerosis in a SOD1-G93A mouse model.

Li Y, Guo Y, Wang X, Yu X, Duan W, Hong K, Wang J, Han H, Li C.

Neuroscience. 2015 Jul 9;298:12-25. doi: 10.1016/j.neuroscience.2015.03.061. Epub 2015 Apr 1.

PMID:
25841320
20.

Amyotrophic lateral sclerosis model derived from human embryonic stem cells overexpressing mutant superoxide dismutase 1.

Wada T, Goparaju SK, Tooi N, Inoue H, Takahashi R, Nakatsuji N, Aiba K.

Stem Cells Transl Med. 2012 May;1(5):396-402. doi: 10.5966/sctm.2011-0061. Epub 2012 May 8.

Supplemental Content

Support Center